Calculate the BASDAI score for ankylosing spondylitis / axial spondyloarthritis. Six questions covering fatigue, pain, stiffness, and enthesitis with guideline-based interpretations.
The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) is the most widely used patient-reported outcome measure for assessing disease activity in ankylosing spondylitis (AS) and axial spondyloarthritis (axSpA). Developed in 1994 at the Royal National Hospital for Rheumatic Diseases in Bath, England, it consists of six questions covering five key symptom domains: fatigue, axial pain, peripheral joint pain, enthesitis, and morning stiffness.
BASDAI scores range from 0 to 10, with higher values indicating more active disease. A score of ≥ 4.0 is the internationally accepted threshold indicating active disease that may benefit from escalation to biologic therapy (TNF inhibitors, IL-17 inhibitors). Most national guidelines — including ASAS-EULAR, NICE, ACR-SAA-SPARTAN, and BSR — require BASDAI ≥ 4.0 (after failure of at least two NSAIDs) as part of their criteria for initiating biologic treatment.
This calculator computes your BASDAI score with domain-level breakdown, compares it to guideline thresholds, and provides a visual disease activity tracker.
BASDAI is the cornerstone patient-reported outcome measure for axial spondyloarthritis. Tracking your BASDAI score between visits helps you and your rheumatologist objectively assess disease activity, measure treatment response, and make evidence-based decisions about therapy escalation. Keep these notes focused on your operational context. Tie the context to the calculator’s intended domain. Use this clarification to avoid ambiguous interpretation.
BASDAI = (Q1 + Q2 + Q3 + Q4 + Mean(Q5, Q6)) / 5 Where: - Q1: Fatigue (0-10) - Q2: Axial spine/neck/hip pain (0-10) - Q3: Peripheral joint pain/swelling (0-10) - Q4: Enthesitis / tenderness to touch (0-10) - Q5: Morning stiffness severity (0-10) - Q6: Morning stiffness duration (hours → 0-10 scale: 2hr = 10)
Result: BASDAI: 5.1 — High disease activity.
Stiffness mean = (7 + 7.5) / 2 = 7.25. BASDAI = (5 + 6 + 3 + 4 + 7.25) / 5 = 5.1. This score exceeds the 4.0 threshold, suggesting biologic therapy may be warranted if NSAIDs have failed.
BASDAI has been a cornerstone of AS management since its validation in the 1990s. It was specifically designed to be simple, quick (<2 minutes to complete), and sensitive to clinically meaningful change. The questionnaire captures the five major symptom domains that patients with AS/axSpA consider most impactful on their quality of life. Its simplicity has made it the most widely translated and used AS outcome measure worldwide.
The BASDAI 50 response criterion — a 50% reduction or absolute decrease of ≥ 2.0 points — is the standard definition of treatment response for biologic therapies. Most guidelines recommend continuing biologic therapy if this threshold is met by 12 weeks, and considering switching if it is not. Studies of TNF inhibitors show BASDAI 50 response rates of 50-60% in clinical practice.
While BASDAI captures the patient perspective, optimal disease assessment combines it with ASDAS (CRP-based composite score), MRI findings (bone marrow edema at sacroiliac joints and spine), and functional measures like BASFI (Bath Functional Index) and BASMi (Bath Metrology Index). Together, these tools provide a comprehensive picture of disease activity, structural damage, and functional impairment.
Lower is better. A BASDAI < 2.0 generally indicates well-controlled or inactive disease. Scores of 2-4 suggest moderate activity that may be managed with NSAIDs. Scores ≥ 4.0 indicate active disease requiring treatment review. The goal of therapy is usually to achieve and maintain a BASDAI < 4.0 or a reduction ≥ 2.0 from baseline.
Most rheumatologists recommend tracking BASDAI at every clinic visit (typically every 3-6 months). If starting a new treatment, more frequent assessments (every 4-6 weeks initially) help determine response. Keeping a diary of scores helps track trends.
BASDAI ≥ 4.0 is used by most guidelines as one criterion for initiating biologic therapy (TNFi, IL-17i) after NSAID failure. A treatment response is typically defined as a BASDAI reduction ≥ 2.0 or ≥ 50%, assessed after 12 weeks of biologic therapy.
ASDAS (Ankylosing Spondylitis Disease Activity Score) combines patient-reported outcomes with C-reactive protein (CRP), making it more objective. ASDAS is increasingly preferred by guidelines but requires blood work. BASDAI remains valuable as a purely patient-reported tool.
Yes. BASDAI is used for both radiographic AS (with visible sacroiliitis on X-ray) and non-radiographic axial spondyloarthritis (nr-axSpA). The same thresholds and treatment algorithms apply.
The developers found that both severity and duration of morning stiffness independently contribute to disease burden. By averaging them, the index captures both dimensions. Duration is converted to a 0-10 scale (2 hours = maximum score of 10) for compatibility with the other questions.